N-carboxy-N-methyl-glycine | 89124-79-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-carboxy-N-methyl-glycine
• 英文别名: N-Carboxy-N-methyl-glycin；Methyl-carboxy-aminoessigsaeure；Sarkosin-N-carbonsaeure；(carboxymethyl-amino)-acetic acid；(carboxymethylamino)acetic acid；N-carboxysarcosine；2-[carboxy(methyl)amino]acetic acid
• CAS: 89124-79-8
• 化学式: C₄H₇NO₄
• 分子量: 133.104
• InChiKey: YSVHIKSKCCPTGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-carboxy-N-methyl-glycine 、 二碳酸二叔丁酯 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 18.0h， 生成 叔丁氧羰酰基肌氨酸
  参考文献：
  名称：

  Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity

  摘要：

  An improved synthesis of the hindered PEG-camptothecin diester transport form has been achieved using the Mukaiyama reagent. We have also assessed the effect of changing the electronic configuration of the (d-position of PEG-camptothecin transport forms on the rates of hydrolysis of the pro-moiety, and attempted to correlate these differences to efficacy in two animal models. In addition to the simple substitution of N for O, other synthetic modifications of these atoms were accomplished by employing heterobifunctional linker groups. The half lives by disappearance (rates of hydrolysis) of the transport forms in buffer and rat plasma were determined. It was established that anchimeric assistance to hydrolytic breakdown of the pro-moiety occurs in a predictable manner for some of these compounds. Results for the new derivatives in a P388 murine leukemic model and HT-29 human colorectal xenograft study are also presented. The use of a glycine linker group was found to provide similar efficacy in rodent models to that of simple camptothecin 20-PEG ester, and displayed enhanced pharmacokinetics. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00005-4

文献信息

• Quinoline derivatives as nk-3 antagonists
  申请人：——

  公开号：US20040097518A1

  公开（公告）日：2004-05-20

  Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: 1 a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  以下式(I)的某些化合物或其药学上可接受的盐或水合物： 1 制备这些化合物的方法，包含这些化合物的药物组合物以及这些化合物和组合物在医学上的用途。
• PHTHALAZINONE DERIVATIVES
  申请人：Javaid Hashim Muhammad

  公开号：US20070093489A1

  公开（公告）日：2007-04-26

  A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y 1 is selected from CH and N, Y 2 is selected from CH and N, Y 3 is selected from CH, CF and N; and (ii) and where Q is O or S; R D is: wherein R N1 is selected from H and optionally substituted C 1-10 alkyl; X is selected from a single bond, NR N2 , CR C3 R C4 and C═O; R N2 is selected from H and optionally substituted C 1-10 alkyl; R C3 and R C4 are independently selected from H, R, C(═O)OR, where R is optionally substituted C 1-10 alkyl, optionally substituted C 5-20 aryl or optionally substituted C 3-20 heterocyclyl; Y is selected from NR N3 and CR C1 R C2 ; R C1 and R C2 are independently selected from H, R, C(═O)OR, where R is optionally substituted C 1-10 alkyl, optionally substituted C 5-20 aryl or optionally substituted C 3-20 heterocyclyl; R C1 and R C2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C 5-7 carbocylic or heterocyclic ring; and when X is a single bond R N1 and R C2 may together with the N and C atoms to which they are bound, form an optionally substituted C 5-7 heterocylic ring; and when X is CR C3 R C4 , R C2 and R C4 may together form an additional bond, such that there is a double bond between the atoms substituted by R C1 and R C3 .

  式(I)的化合物：其中：A和B一起代表一个可选择取代的、融合的芳香环；D选择自：(i)其中Y1选择自CH和N，Y2选择自CH和N，Y3选择自CH、CF和N；和(ii)其中Q是O或S；RD是：其中RN1选择自H和可选择取代的C1-10烷基；X选择自单键、NRN2、CRC3RC4和C═O；RN2选择自H和可选择取代的C1-10烷基；RC3和RC4独立选择自H、R、C(═O)OR，其中R是可选择取代的C1-10烷基、可选择取代的C5-20芳基或可选择取代的C3-20杂环烷基；Y选择自NRN3和CRC1RC2；RC1和RC2独立选择自H、R、C(═O)OR，其中R是可选择取代的C1-10烷基、可选择取代的C5-20芳基或可选择取代的C3-20杂环烷基；RC1和RC2与它们连接的碳原子一起可以形成一个可选择取代的螺联的C5-7碳环或杂环；当X是单键时，RN1和RC2可以与它们连接的N和C原子一起形成一个可选择取代的C5-7杂环；当X是CRC3RC4时，RC2和RC4可以一起形成一个额外的键，使得由RC1和RC3取代的原子之间有一个双键。
• Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity
  作者：R Greenwald

  DOI：10.1016/s0968-0896(98)00005-4

  日期：1998.5

  An improved synthesis of the hindered PEG-camptothecin diester transport form has been achieved using the Mukaiyama reagent. We have also assessed the effect of changing the electronic configuration of the (d-position of PEG-camptothecin transport forms on the rates of hydrolysis of the pro-moiety, and attempted to correlate these differences to efficacy in two animal models. In addition to the simple substitution of N for O, other synthetic modifications of these atoms were accomplished by employing heterobifunctional linker groups. The half lives by disappearance (rates of hydrolysis) of the transport forms in buffer and rat plasma were determined. It was established that anchimeric assistance to hydrolytic breakdown of the pro-moiety occurs in a predictable manner for some of these compounds. Results for the new derivatives in a P388 murine leukemic model and HT-29 human colorectal xenograft study are also presented. The use of a glycine linker group was found to provide similar efficacy in rodent models to that of simple camptothecin 20-PEG ester, and displayed enhanced pharmacokinetics. (C) 1998 Elsevier Science Ltd. All rights reserved.